⏳ Fetching live dividend data...
Home › Calculator › VIRX Dividend Calculator 2026
Viracta Therapeutics, Inc. · OTC
Price: $0.01 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in VIRX → $4.522526406501944e+34M in 10 years · $3,768,754,008,145,728,000,000,000,000,000,000,000,000.00/month
Viracta Therapeutics, Inc. operates as a precision oncology firm, specializing in the development of therapeutic agents aimed at treating cancers linked to viral infections. The company's leading drug candidate, Nana-val (a combination of nanatinostat and valganciclovir), is currently advancing through multiple clinical trials. It is in Phase II development for Epstein-Barr virus-positive (EBV+) lymphoma. Furthermore, Nana-val is being evaluated in an open-label Phase 2 basket trial, which targets various forms of relapsed/refractory EBV+ lymphoma, and an open-label Phase 1b/2 trial for EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Beyond its flagship program, Viracta's pipeline features vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor, and VRx-510 (previously known as SNS-510), a PDK-1 inhibitor in its preclinical phase. The company is actively exploring opportunities for development and potential collaborations, particularly for vecabrutinib in conjunction with chimeric antigen receptor (CAR) T-cell therapies, and for VRx-510 across diverse oncological indications. Established in 1998, the company changed its name from Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. on February 25, 2021. Its corporate headquarters are located in Cardiff-by-the-Sea, California.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open VIRX position with:
Real after-tax yield depends on where you live and how you hold VIRX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 20449.90% | 20447.10% | $2,044,990 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 17382.42% | 17379.62% | $1,738,242 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 16359.92% | 16357.12% | $1,635,992 / yr |
| 🇬🇧 UK ISA | 0% | 20449.90% | 20447.10% | $2,044,990 / yr |
| 🇬🇧 UK Taxable | 8.75% | 18660.53% | 18657.73% | $1,866,053 / yr |
| 🇨🇦 TFSA | 0% | 20449.90% | 20447.10% | $2,044,990 / yr |
| 🇨🇦 CA Taxable | 25% | 15337.43% | 15334.63% | $1,533,743 / yr |
| 🇦🇺 Super (pension) | 15% | 17382.42% | 17379.62% | $1,738,242 / yr |
| 🇦🇺 AU Taxable | 30% | 14314.93% | 14312.13% | $1,431,493 / yr |
| 🇩🇪 DE Taxable | 26.375% | 15056.24% | 15053.44% | $1,505,624 / yr |
| 🇫🇷 FR Taxable | 30% | 14314.93% | 14312.13% | $1,431,493 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
VIRX pays quarterly — 4 times per year. Next ex-div: TBD.
How VIRX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for VIRX sourced from FMP /financial-growth endpoint — real data, not estimates.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the VIRX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Viracta Therapeutics, Inc. (VIRX) is currently trading at $0.01, trading near its 52-week low. The current dividend yield is 20449.90% based on an annual payout of $2.00 per share.
Viracta Therapeutics, Inc. (VIRX) is a healthcare stock currently trading at $0.01 with a dividend yield of 20449.90%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →